16 September 2026 editorial review · Trial
LY3938577: glucose-sensitive insulin in type 1 diabetes: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Corrected primary endpoints to include pharmacokinetics as well as safety. Distinguished healthy Part A from T1D cohorts, diagnosis duration, lowC-peptide and pump criteria. No results or proof of glucose-responsive action.
Registry: NCT06280703; RECRUITING; updated 2026-01-20; enrollment 118 (ESTIMATED); results not posted.
Endpoint comparison: Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration. (Baseline up to Approximately Week 11); Part B and D: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration. (Baseline up to Week 10); Part A: Number of Participants With Clinically Significant Changes in Vital Signs (Baseline up to Approximately Week 11); Part B: Number of Participants With Clinically Significant Changes in Vital Signs (Baseline up to Week 10); Part A: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters (Baseline up to Approximately Week 11); Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters (Baseline up to Week 10); Part A: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577 (Predose on day 1 up to week 13 post dose); Part A: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577 (Predose on day 1 up to week 13 post dose); Part B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577 (Predose on day 1 up to week 13 post dose); Part C: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577 (Predose on day 1 up to week 13 post dose); Part D: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577 (Predose on day 1 up to week 13 post dose); Part A: PK: Maximum Observed Concentration (Cmax) of LY3938577 (Predose on day 1 up to week 13 post dose); Part B: PK: Maximum Observed Concentration (Cmax) of LY3938577 (Predose on day 1 up to week 13 post dose); Part C: PK: Concentration of LY3938577 (Predose on day 1 up to week 13 post dose).
Sources for this record: A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.